A randomized phase II study of gemcitabine plus Z-360, a CCK2 receptor-selective antagonist, in patients with metastatic pancreatic cancer as compared with gemcitabine plus placebo

BACKGROUND: We investigated the efficacy and safety of 60, 120, or 240 mg of Z-360, which is a highly potent cholecystokinin2-receptor-selective antagonist, combined with gemcitabine in patients with metastatic pancreatic cancer. METHODS: Patients were randomly assigned in a 1:1:1:1 ratio to one of...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Cancer Chemother Pharmacol
Autori principali: Ueno, Makoto, Li, Chung Pin, Ikeda, Masafumi, Ishii, Hiroshi, Mizuno, Nobumasa, Yamaguchi, Taketo, Ioka, Tatsuya, Oh, Do Youn, Ichikawa, Wataru, Okusaka, Takuji, Matsuyama, Yutaka, Arai, Daichi, Chen, Li Tzong, Park, Young Suk, Furuse, Junji
Natura: Artigo
Lingua:Inglês
Pubblicazione: Springer Berlin Heidelberg 2017
Soggetti:
Original Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5532401/
https://ncbi.nlm.nih.gov/pubmed/28634650
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00280-017-3351-4
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi